Clinical Trial Update: Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC [Phase 3]

View source ↗

Summary

Phase 3 trial exploring almonertinib plus chemotherapy as first-line treatment for EGFR-mutant NSCLC with concomitant non-EGFR driver mutations.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Almonertinib (almonertinib)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN